Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,531,896 shares of TARS stock, worth $121 Million. This represents 5.35% of its overall portfolio holdings.
Number of Shares
2,531,896
Previous 2,440,445
3.75%
Holding current value
$121 Million
Previous $80.3 Million
74.66%
% of portfolio
5.35%
Previous 2.89%
Shares
5 transactions
Others Institutions Holding TARS
# of Institutions
201Shares Held
40.5MCall Options Held
72.7KPut Options Held
313K-
Black Rock Inc. New York, NY3.27MShares$156 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.24MShares$155 Million2.92% of portfolio
-
Jennison Associates LLC2.5MShares$120 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$108 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.12MShares$101 Million0.0% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.28B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...